Abstract: For neuromorphic engineering to emulate the human brain, improving memory density with low power consumption is an indispensable but challenging goal. In this regard, emerging RRAMs have ...

JERUSALEM - Entera Bio Ltd. (NASDAQ:ENTX) announced new preclinical data supporting the development of a once-daily tablet for hypoparathyroidism patients using its proprietary long-acting parathyroid ...

Lamba Sanjiv, Chief Executive Officer of LINDE PLC (NYSE:LIN), acquired 2,520 shares of the company’s ordinary shares on December 8, 2025, in a purchase transaction. The shares were bought at a ...

This page may contain affiliate links to legal sports betting partners. If you sign up or place a wager, FOX Sports may be compensated. Read more about Sports Betting on FOX Sports. A prop bet is a ...

Management to host Q3 2025 update at 5:00PM Eastern Time, today. LOS ANGELES, CALIFORNIA / ACCESS Newswire / November 13, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of ...

Westerville residents are voting on a citizen-initiated charter amendment that could force the city to offer outdated utility metering technology over claims from some residents about microwave health ...

Apple is announcing a major expansion and redesign of its bug bounty program, doubling maximum payouts, adding new research categories, and introducing a more transparent reward structure. Since the ...

Recent progress in both analog and digital quantum simulations heralds a future in which quantum computers could simulate — and thereby illuminate — physical phenomena that are far too complex for ...

Low-code and modular programming environments are transforming PLC programming, with vendors providing pre-packaged libraries and objects that eliminate traditional IEC-61131-3 style coding, allowing ...

The tool, Codex, will be able to handle multiple tasks at the same time, the company said. OpenAI is also in talks to acquire a coding tool called Windsurf for $3 billion. By Cade Metz Cade Metz ...

- Patient dosing continues in APPROACH, Cybin’s first pivotal Phase 3 study of CYB003 for the adjunctive treatment for Major Depressive Disorder (“MDD”) - The patent, which is expected to provide ...